Comparing Syros Pharmaceuticals (SYRS) and Cardiome Pharma Corporation (CRME)
Cardiome Pharma Corporation (NASDAQ: CRME) and Syros Pharmaceuticals (NASDAQ:SYRS) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, risk, profitability and earnings.
This is a summary of current ratings for Cardiome Pharma Corporation and Syros Pharmaceuticals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Cardiome Pharma Corporation||0||0||3||0||3.00|
Cardiome Pharma Corporation currently has a consensus price target of $7.58, indicating a potential upside of 422.99%. Syros Pharmaceuticals has a consensus price target of $26.14, indicating a potential upside of 130.51%. Given Cardiome Pharma Corporation’s stronger consensus rating and higher possible upside, equities analysts plainly believe Cardiome Pharma Corporation is more favorable than Syros Pharmaceuticals.
Volatility and Risk
Cardiome Pharma Corporation has a beta of 0.91, meaning that its share price is 9% less volatile than the S&P 500. Comparatively, Syros Pharmaceuticals has a beta of -3.33, meaning that its share price is 433% less volatile than the S&P 500.
This table compares Cardiome Pharma Corporation and Syros Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Cardiome Pharma Corporation||-110.95%||-78.51%||-38.30%|
Institutional & Insider Ownership
55.1% of Cardiome Pharma Corporation shares are owned by institutional investors. Comparatively, 59.8% of Syros Pharmaceuticals shares are owned by institutional investors. 33.6% of Syros Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Valuation and Earnings
This table compares Cardiome Pharma Corporation and Syros Pharmaceuticals’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||NetIncome||Earnings Per Share||Price/Earnings Ratio|
|Cardiome Pharma Corporation||$25.26 million||1.94||-$19.61 million||($0.83)||-1.75|
|Syros Pharmaceuticals||$320,000.00||932.01||-$47.74 million||($2.01)||-5.64|
Cardiome Pharma Corporation has higher revenue and earnings than Syros Pharmaceuticals. Syros Pharmaceuticals is trading at a lower price-to-earnings ratio than Cardiome Pharma Corporation, indicating that it is currently the more affordable of the two stocks.
Cardiome Pharma Corporation beats Syros Pharmaceuticals on 7 of the 13 factors compared between the two stocks.
Cardiome Pharma Corporation Company Profile
Cardiome Pharma Corp. (Cardiome) is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of cardiovascular therapies for heart disease. The Company’s segments are Europe and Rest of World. Cardiome has two marketed, in-hospital, cardiology products, which include BRINAVESS (vernakalant IV), approved in Europe and other territories for the conversion of onset atrial fibrillation (AF) to sinus rhythm in adults, and AGGRASTAT (tirofiban hydrochloride (HCl)), indicated for use in patients with acute coronary syndrome. Cardiome also commercializes ESMOCARD and ESMOCARD LYO (esmolol hydrochloride), a short-acting beta-blocker used to control heart rate in various cardiovascular indications, in select European markets. Cardiome has also licensed TREVYENT, a development-stage drug device combination product that is under development for pulmonary arterial hypertension, in certain regions outside the United States.
Syros Pharmaceuticals Company Profile
Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines. The Company’s drug programs include SY-1425 (retinoic acid receptor alpha (RARa) agonist) and SY-1365 (cyclin-dependent kinase 7 (CDK7) inhibitor). SY-1425 (tamibarotene) is an oral, potent and selective agonist, or activator, of the transcription factor RARa. SY-1365 is a small molecule inhibitor of the transcriptional kinase known as CDK7. The Company is using its platform to analyze gene expression programs across additional cancers, inflammatory diseases and other diseases to identify optimal points of therapeutic intervention in specific subsets of patients.
Receive News & Ratings for Cardiome Pharma Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiome Pharma Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.